| 1 | Exploring sexual function in adrenal insufficiency: findings from the Dual RElease hydrocortisone versus conventionAl glucocorticoid replaceMent therapy in hypocortisolism (DREAM) trial | 3.3 | 6 | Citations (PDF) |
| 2 | Long‐term penile prosthesis couple's satisfaction: A systematic review and meta‐analysis | 3.3 | 5 | Citations (PDF) |
| 3 | Does an increase in adipose tissue ‘weight’ affect male fertility? A systematic review and meta‐analysis based on semen analysis performed using the WHO 2010 criteria | 3.3 | 44 | Citations (PDF) |
| 4 | Effect of antioxidants on semen parameters in men with oligo‐astheno‐teratozoospermia: a network meta‐analysis | 3.3 | 11 | Citations (PDF) |
| 5 | Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center | 3.0 | 7 | Citations (PDF) |
| 6 | Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care | 7.1 | 4 | Citations (PDF) |
| 7 | Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease | 3.0 | 9 | Citations (PDF) |
| 8 | Risk Assessment of Diabetes Mellitus During and After Pregnancy in Women With Prolactinomas | 4.2 | 4 | Citations (PDF) |
| 9 | Cardiac magnetic resonance reveals biventricular impairment in Cushing’s syndrome: a multicentre case-control study | 2.6 | 2 | Citations (PDF) |
| 10 | The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study | 2.8 | 15 | Citations (PDF) |
| 11 | Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly 2024, 2, | | 2 | Citations (PDF) |
| 12 | 1,25‑Dihydroxyvitamin D3 mitigates the adipogenesis induced by bisphenol A in 3T3-L1 and hAMSC through miR-27-3p regulation | 3.2 | 6 | Citations (PDF) |
| 13 | Evaluating the Impact of Continuous Glucose Monitoring on Erectile Dysfunction in Type 1 Diabetes: A Focus on Reducing Glucose Variability and Inflammation | 2.3 | 1 | Citations (PDF) |
| 14 | Dietary Habits, Physical Activity and Body Mass Index in Transgender and Gender Diverse Adults in Italy: A Voluntary Sampling Observational Study | 4.7 | 6 | Citations (PDF) |
| 15 | Fertility in Acromegaly: A Single-Center Experience of Female Patients During Active Disease and After Disease Remission | 4.2 | 9 | Citations (PDF) |
| 16 | Early Left Ventricular Diastolic Dysfunction in Females with Chronic Hyperprolactinemia: A Doppler Echocardiographic Study | 2.6 | 4 | Citations (PDF) |
| 17 | Approach to the Patient With Prolactinoma | 4.2 | 75 | Citations (PDF) |
| 18 | Unmet needs on the current medical management of Cushing’s syndrome: results from a Delphi panel of Italian endocrinologists | 3.0 | 8 | Citations (PDF) |
| 19 | Psychopathology in Acromegaly—Real and Perceived | 4.2 | 7 | Citations (PDF) |
| 20 | Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement | 36.0 | 264 | Citations (PDF) |
| 21 | The environment and male reproductive system: the potential role and underlying mechanisms of cadmium in testis cancer | 3.6 | 4 | Citations (PDF) |
| 22 | Circulating myomiRNAs as biomarkers in patients with Cushing’s syndrome | 3.0 | 6 | Citations (PDF) |
| 23 | Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms | 4.1 | 16 | Citations (PDF) |
| 24 | Interferenti endocrini e funzione gonadica: focus su steroidogenesi testicolare e infertilità maschile | 0.0 | 1 | Citations (PDF) |
| 25 | Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial | 3.0 | 13 | Citations (PDF) |
| 26 | Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity | 3.5 | 12 | Citations (PDF) |
| 27 | The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review | 7.9 | 34 | Citations (PDF) |
| 28 | The dopaminergic control of Cushing’s syndrome | 3.0 | 17 | Citations (PDF) |
| 29 | Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma | 2.7 | 6 | Citations (PDF) |
| 30 | Andrological effects of SARS-Cov-2 infection: a systematic review and meta-analysis | 3.0 | 52 | Citations (PDF) |
| 31 | MicroRNAs and Long Non-Coding RNAs in Adrenocortical Carcinoma | 4.8 | 8 | Citations (PDF) |
| 32 | Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study | 3.0 | 10 | Citations (PDF) |
| 33 | Testis-Specific Genes Deregulation in the Testis of COVID-19 Patients: A Potential Driver of Spermatogenesis Disruption? | 4.2 | 1 | Citations (PDF) |
| 34 | Etiology-, Sex-, and Tumor Size-Based Differences in Adrenocorticotropin-Dependent Cushing Syndrome | 3.5 | 7 | Citations (PDF) |
| 35 | Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis | 7.1 | 188 | Citations (PDF) |
| 36 | Sperm Global DNA Methylation (SGDM) in Semen of Healthy Dogs | 2.0 | 3 | Citations (PDF) |
| 37 | Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study | 4.1 | 23 | Citations (PDF) |
| 38 | Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health | 3.0 | 29 | Citations (PDF) |
| 39 | Levoketoconazole: a novel treatment for endogenous Cushing's syndrome | 3.1 | 14 | Citations (PDF) |
| 40 | Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study | 4.1 | 61 | Citations (PDF) |
| 41 | When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis | 3.5 | 22 | Citations (PDF) |
| 42 | Hyperprolactinemia after menopause: Diagnosis and management | 3.1 | 15 | Citations (PDF) |
| 43 | Consensus on diagnosis and management of Cushing's disease: a guideline update | 22.6 | 736 | Citations (PDF) |
| 44 | Subclinical male hypogonadism | 1.2 | 10 | Citations (PDF) |
| 45 | A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score | 4.1 | 23 | Citations (PDF) |
| 46 | Glucocorticoid excess and COVID-19 disease | 7.1 | 44 | Citations (PDF) |
| 47 | Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials | 4.1 | 114 | Citations (PDF) |
| 48 | Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase | 22.6 | 185 | Citations (PDF) |
| 49 | MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study | 0.3 | 3 | Citations (PDF) |
| 50 | Long-acting pasireotide improves clinical signs and quality of life in Cushing’s disease: results from a phase III study | 3.0 | 24 | Citations (PDF) |
| 51 | Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells | 4.7 | 119 | Citations (PDF) |
| 52 | Bisphenol A: an emerging threat to female fertility | 4.3 | 226 | Citations (PDF) |
| 53 | Erectile dysfunction and cardiovascular risk: a review of current findings | 1.9 | 58 | Citations (PDF) |
| 54 | Smoke, alcohol and drug addiction and female fertility | 4.3 | 141 | Citations (PDF) |
| 55 | Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma | 4.0 | 37 | Citations (PDF) |
| 56 | Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement | 3.2 | 17 | Citations (PDF) |
| 57 | People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction | 3.0 | 53 | Citations (PDF) |
| 58 | Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome | 2.8 | 23 | Citations (PDF) |
| 59 | ACTH increment post total bilateral adrenalectomy for Cushing’s disease: a consistent biosignature for predicting Nelson’s syndrome | 2.8 | 16 | Citations (PDF) |
| 60 | Advances in the medical treatment of Cushing's syndrome | 22.6 | 128 | Citations (PDF) |
| 61 | Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us? | 1.5 | 22 | Citations (PDF) |
| 62 | Acromegaly and Heart Failure | 2.2 | 46 | Citations (PDF) |
| 63 | Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit | 3.5 | 26 | Citations (PDF) |
| 64 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial | 22.6 | 91 | Citations (PDF) |
| 65 | Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the Amico‐Andrologo survey | 3.3 | 45 | Citations (PDF) |
| 66 | Acromegaly | 50.7 | 350 | Citations (PDF) |
| 67 | The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence” | 2.6 | 41 | Citations (PDF) |
| 68 | Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study | 2.8 | 24 | Citations (PDF) |
| 69 | Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs | 7.1 | 31 | Citations (PDF) |
| 70 | OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3) | 0.3 | 3 | Citations (PDF) |
| 71 | SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas | 0.3 | 7 | Citations (PDF) |
| 72 | SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM) | 0.3 | 1 | Citations (PDF) |
| 73 | Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study | 2.6 | 22 | Citations (PDF) |
| 74 | Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial | 22.6 | 152 | Citations (PDF) |
| 75 | Air pollution and female fertility: a systematic review of literature | 4.3 | 166 | Citations (PDF) |
| 76 | Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting | 2.6 | 13 | Citations (PDF) |
| 77 | Recombinant FSH Improves Sperm DNA Damage in Male Infertility: A Phase II Clinical Trial | 4.1 | 27 | Citations (PDF) |
| 78 | Smoke, alcohol and drug addiction and male fertility | 4.3 | 227 | Citations (PDF) |
| 79 | Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer | 4.2 | 29 | Citations (PDF) |
| 80 | Shedding new light on female fertility: The role of vitamin D | 7.1 | 119 | Citations (PDF) |
| 81 | Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities | 2.8 | 197 | Citations (PDF) |
| 82 | Pegvisomant in acromegaly: an update | 3.0 | 70 | Citations (PDF) |
| 83 | Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance | 2.6 | 17 | Citations (PDF) |
| 84 | Cardiovascular alterations in adult GH deficiency | 5.4 | 35 | Citations (PDF) |
| 85 | The environment and male reproduction: The effect of cadmium exposure on reproductive function and its implication in fertility | 2.8 | 241 | Citations (PDF) |
| 86 | The role of vitamin D in male fertility: A focus on the testis | 7.1 | 97 | Citations (PDF) |
| 87 | Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies | 2.6 | 7 | Citations (PDF) |
| 88 | Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson’s disease | 2.4 | 41 | Citations (PDF) |
| 89 | Influence of Bisphenol A on Type 2 Diabetes Mellitus | 3.1 | 80 | Citations (PDF) |
| 90 | Investigation of sperm telomere length as a potential marker of paternal genome integrity and semen quality | 2.8 | 76 | Citations (PDF) |
| 91 | Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study | 2.6 | 30 | Citations (PDF) |
| 92 | Complications of Cushing's syndrome: state of the art | 22.6 | 533 | Citations (PDF) |
| 93 | The effect of FT500 Plus ® on ovarian stimulation in PCOS women | 2.8 | 28 | Citations (PDF) |
| 94 | Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis | 3.6 | 30 | Citations (PDF) |
| 95 | The safety of treatments for prolactinomas | 2.7 | 21 | Citations (PDF) |
| 96 | The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome | 2.6 | 39 | Citations (PDF) |
| 97 | Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly | 2.6 | 50 | Citations (PDF) |
| 98 | Cushing’s disease: the burden of illness | 2.6 | 159 | Citations (PDF) |
| 99 | Association between vitamin D and sperm parameters: Clinical evidence | 2.6 | 38 | Citations (PDF) |
| 100 | Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib | 2.6 | 10 | Citations (PDF) |
| 101 | Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study | 2.6 | 16 | Citations (PDF) |
| 102 | Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland | 2.6 | 22 | Citations (PDF) |
| 103 | The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma | 1.7 | 22 | Citations (PDF) |
| 104 | Erectile Dysfunction Is Common among Men with Acromegaly and Is Associated with Morbidities Related to the Disease | 0.5 | 30 | Citations (PDF) |
| 105 | Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation | 3.2 | 28 | Citations (PDF) |
| 106 | Neuropsychiatric disorders in Cushing's syndrome | 2.8 | 157 | Citations (PDF) |
| 107 | The Treatment of Cushing's Disease | 25.8 | 426 | Citations (PDF) |
| 108 | Adverse events associated with somatostatin analogs in acromegaly | 2.7 | 47 | Citations (PDF) |
| 109 | The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center | 2.6 | 45 | Citations (PDF) |
| 110 | Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease | 2.8 | 149 | Citations (PDF) |
| 111 | Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly | 0.0 | 2 | Citations (PDF) |
| 112 | Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline | 3.0 | 27 | Citations (PDF) |
| 113 | Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration | 3.0 | 5 | Citations (PDF) |
| 114 | A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients | 3.0 | 16 | Citations (PDF) |
| 115 | Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing’s syndrome | 3.0 | 23 | Citations (PDF) |
| 116 | The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues | 3.0 | 37 | Citations (PDF) |
| 117 | Growth hormone, prolactin, and sexuality | 3.0 | 71 | Citations (PDF) |
| 118 | Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline | 3.0 | 48 | Citations (PDF) |
| 119 | Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status | 3.0 | 38 | Citations (PDF) |
| 120 | LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study | 4.2 | 183 | Citations (PDF) |
| 121 | A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency | 2.4 | 27 | Citations (PDF) |
| 122 | Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase <scp>III</scp> study | 2.5 | 113 | Citations (PDF) |
| 123 | Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial | 2.8 | 59 | Citations (PDF) |
| 124 | Investigational therapies for acromegaly | 4.0 | 14 | Citations (PDF) |
| 125 | Preoperative workup in the assessment of adrenal incidentalomas: outcome from 282 consecutive laparoscopic adrenalectomies | 1.6 | 28 | Citations (PDF) |
| 126 | The Metabolic Profile in Active Acromegaly is Gender-Specific | 4.2 | 62 | Citations (PDF) |
| 127 | Results of a Single-Center Observational 10-Year Survey Study on Recurrence of Hyperprolactinemia after Pregnancy and Lactation | 4.2 | 98 | Citations (PDF) |
| 128 | Molecular basis of pharmacological therapy in Cushing’s disease | 2.6 | 29 | Citations (PDF) |
| 129 | Identification of vitamin D (VDR) and retinoic X (RXR) receptor in normal and neoplastic human reproductive tissues | 0.0 | 2 | Citations (PDF) |
| 130 | Cardiac Abnormalities in Acromegaly | 0.9 | 28 | Citations (PDF) |
| 131 | Subclinical Cushing’s syndrome | 5.4 | 58 | Citations (PDF) |
| 132 | Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature | 2.5 | 68 | Citations (PDF) |
| 133 | Resistance to Somatostatin Analogs in Acromegaly | 25.8 | 241 | Citations (PDF) |
| 134 | Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study | 2.8 | 38 | Citations (PDF) |
| 135 | Medical Treatment of Cushing’s Disease with Pasireotide | 2.6 | 5 | Citations (PDF) |
| 136 | Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study | 4.2 | 59 | Citations (PDF) |
| 137 | Impact of Somatostatin AnalogsVersusSurgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study | 4.2 | 57 | Citations (PDF) |
| 138 | Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study | 4.2 | 144 | Citations (PDF) |
| 139 | Significant tumour shrinkage after 12 months of lanreotide Autogel‐120 mg treatment given first‐line in acromegaly | 2.5 | 68 | Citations (PDF) |
| 140 | The Medical Treatment of Cushing’s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery | 4.2 | 320 | Citations (PDF) |
| 141 | The accuracy of the arginine growth hormone test in Parkinsonism | 4.6 | 0 | Citations (PDF) |
| 142 | Cushing's Syndrome | 3.7 | 186 | Citations (PDF) |
| 143 | Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy | 4.2 | 85 | Citations (PDF) |
| 144 | Correlation of in Vitro and in Vivo Somatotropic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy | 4.2 | 119 | Citations (PDF) |
| 145 | Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors | 4.2 | 67 | Citations (PDF) |
| 146 | Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance | 4.2 | 85 | Citations (PDF) |
| 147 | Cushing's syndrome: aftermath of the cure | 1.6 | 83 | Citations (PDF) |
| 148 | Bone Demineralization and Vertebral Fractures in Endogenous Cortisol Excess: Role of Disease Etiology and Gonadal Status | 4.2 | 143 | Citations (PDF) |
| 149 | Sulfur Amino Acids in Cushing’s Disease: Insight in Homocysteine and Taurine Levels in Patients with Active and Cured Disease | 4.2 | 34 | Citations (PDF) |
| 150 | The Metabolic Syndrome and Cardiovascular Risk in Cushing's Syndrome | 3.7 | 157 | Citations (PDF) |
| 151 | Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal Tumors | 4.2 | 74 | Citations (PDF) |
| 152 | Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors | 4.2 | 255 | Citations (PDF) |
| 153 | Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment | 4.2 | 124 | Citations (PDF) |
| 154 | Reversal of acromegalic cardiomyopathy in young but not in middle‐aged patients after 12 months of treatment with the depot long‐acting somatostatin analogue octreotide | 2.5 | 104 | Citations (PDF) |
| 155 | Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study | 2.5 | 110 | Citations (PDF) |
| 156 | High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study | 4.2 | 127 | Citations (PDF) |
| 157 | Nephrolithiasis in Cushing’s Disease: Prevalence, Etiopathogenesis, and Modification after Disease Cure | 4.2 | 98 | Citations (PDF) |
| 158 | Central Diabetes Insipidus and Autoimmunity: Relationship between the Occurrence of Antibodies to Arginine Vasopressin-Secreting Cells and Clinical, Immunological, and Radiological Features in a Large Cohort of Patients with Central Diabetes Insipidus of Known and Unknown Etiology | 4.2 | 117 | Citations (PDF) |
| 159 | Cardiovascular Risk Factors and Common Carotid Artery Caliber and Stiffness in Patients with Cushing’s Disease during Active Disease and 1 Year after Disease Remission | 4.2 | 343 | Citations (PDF) |
| 160 | Short-Term Suppression of GH and IGF-I Levels Improves Gonadal Function and Sperm Parameters in Men with Acromegaly | 4.2 | 41 | Citations (PDF) |
| 161 | Early Vascular Alterations in Acromegaly | 4.2 | 101 | Citations (PDF) |
| 162 | The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study | 4.2 | 102 | Citations (PDF) |
| 163 | Cardiovascular Consequences of Early-Onset Growth Hormone Excess | 4.2 | 87 | Citations (PDF) |
| 164 | Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood‐onset and adulthood‐onset disease | 2.5 | 72 | Citations (PDF) |
| 165 | Early Vascular Alterations in Acromegaly | 4.2 | 20 | Citations (PDF) |
| 166 | Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance | 2.5 | 8 | Citations (PDF) |
| 167 | Increased arterial intima‐media thickness by B‐M mode echodoppler ultrasonography in acromegaly | 2.5 | 104 | Citations (PDF) |
| 168 | Reply | 2.5 | 0 | Citations (PDF) |
| 169 | Title is missing! | 2.8 | 27 | Citations (PDF) |
| 170 | Title is missing! | 2.8 | 36 | Citations (PDF) |
| 171 | Title is missing! | 2.8 | 1 | Citations (PDF) |
| 172 | Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy | 4.2 | 216 | Citations (PDF) |
| 173 | Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance* | 4.2 | 103 | Citations (PDF) |
| 174 | Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization | 2.5 | 96 | Citations (PDF) |
| 175 | Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study | 2.5 | 40 | Citations (PDF) |
| 176 | The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas | 2.5 | 82 | Citations (PDF) |
| 177 | Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease | 2.5 | 57 | Citations (PDF) |
| 178 | Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients1 | 4.2 | 179 | Citations (PDF) |
| 179 | Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism<sup>1</sup> | 4.2 | 166 | Citations (PDF) |
| 180 | Persistence of Increased Cardiovascular Risk in Patients with Cushing’s Disease after Five Years of Successful Cure | 4.2 | 356 | Citations (PDF) |
| 181 | Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus | 4.2 | 18 | Citations (PDF) |
| 182 | The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency | 4.2 | 95 | Citations (PDF) |
| 183 | Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects | 4.2 | 72 | Citations (PDF) |
| 184 | Title is missing! | 2.8 | 83 | Citations (PDF) |
| 185 | The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency | 4.2 | 31 | Citations (PDF) |
| 186 | Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects | 4.2 | 23 | Citations (PDF) |
| 187 | Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus | 4.2 | 5 | Citations (PDF) |
| 188 | Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease | 2.5 | 13 | Citations (PDF) |
| 189 | Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease | 2.5 | 86 | Citations (PDF) |
| 190 | Impairment of Bone Status in Patients with Central Diabetes Insipidus* | 4.2 | 24 | Citations (PDF) |
| 191 | Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males | 4.2 | 39 | Citations (PDF) |
| 192 | Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage | 4.2 | 155 | Citations (PDF) |
